GetTopicDetailResponse(id=9229124499a1, topicName=ARX788, introduction=, content=乳腺癌 卡培他濱 拉帕替尼 ARX788, image=null, comments=0, allHits=360, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sat Feb 22 10:22:22 CST 2025, time=2025-02-22, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=113897, tagList=[TagDto(tagId=113897, tagName=ARX788)], ipAttribution=四川省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2253067, encodeId=03cc225306e3e, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他濱#</a> <a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a> <a href='/topic/show?id=9229124499a1' target=_blank style='color:#2F92EE;'>#ARX788#</a>, objectTitle=STTT：ARX788與拉帕替尼聯(lián)合卡培他濱治療HER2陽性晚期乳腺癌的隨機III期臨床試驗, objectType=article, longId=863823, objectId=3e0d86382356, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240718/1721282756373_92910.jpg, objectUrl=/article/show_article.do?id=3e0d86382356, replyNumber=0, likeNumber=52, createdTime=2025-02-22, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=四川省, moduleDTOList=[ModuleDTO(moduleId=3e0d86382356, moduleTitle=STTT：ARX788與拉帕替尼聯(lián)合卡培他濱治療HER2陽性晚期乳腺癌的隨機III期臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3e0d86382356)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-02-22發(fā)表于四川省
